iOnctura
iOnctura is a Switzerland-based biotechnology company running 2 late-stage cancer trials of roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma.
Overview
iOnctura, based in Geneva, Switzerland, is a biotechnology company. iOnctura is a biotech company developing precision oral small-molecule drugs that target the tumour-stroma-immune interface in neglected and hard-to-treat cancers. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma. The largest, NCT06717126 (A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma), plans to enrol 85 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyAura Biosciences
Shares Uveal melanoma, Melanoma and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Uveal melanoma, Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.